Ten Stocks Trending on Discord for Thursday October 13, 2022: MMAT, ANPC, RLMD, APDN, COMS, IMUX, AVCT, REV, FNHC, TSLA
$ANPC
$APDN
$AVCT
$COMS
Medical Specialities
Health Care
Other Consumer Services
Consumer Discretionary
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/25/2024 | $10.00 | Buy | H.C. Wainwright | |
| 10/24/2024 | $120.00 → $125.00 | Underweight | Wells Fargo | |
| 10/24/2024 | $236.00 → $238.00 | Hold | Truist | |
| 10/24/2024 | $165.00 → $195.00 | Hold | Jefferies | |
| 10/24/2024 | $245.00 → $255.00 | Neutral | Cantor Fitzgerald | |
| 10/24/2024 | $230.00 → $250.00 | Neutral | Goldman | |
| 10/24/2024 | $236.00 → $249.00 | Outperform | RBC Capital Mkts | |
| 10/24/2024 | $254.00 → $278.00 | Buy | Canaccord Genuity |
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
4 - RELMADA THERAPEUTICS, INC. (0001553643) (Issuer)
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Jefferies London Healthcare Conference details: Presentation:Wednesday, November 20, 2024 at 12:00 PM GMTSpeaker:Sergio Traversa, CEORegistration:Webcast link The replay of the webcast will be available on the "For Investors/Events" page of the Relmada website for 90 days following the conference. Ab
NEW YORK, Nov. 19, 2024 /PRNewswire/ -- SunCar Technology Group Inc. (NASDAQ:SDA), a leading innovator in cloud-based B2B auto services and auto e-insurance in China, is pleased to announce its inclusion in the NASDAQ Golden Dragon China Index, marking an important milestone in the Company's growth journey. The NASDAQ Golden Dragon China Index is a benchmark for tracking Chinese companies listed on U.S. exchanges, offering investors a window into the dynamic growth opportunities within China's economy, particularly in sectors like digital services, technology, new consumer markets, and clean energy. This prestigious index includes leading Chinese companies like Alibaba (NYSE:BABA), JD.com (
REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight subjects With positive results, Phase 2a proof-of-concept study expected to begin in H1 2025 CORAL GABLES, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the initiation of dosing in a Phase 1 SAD study of REL-P11, an investigational agent for metabolic disease. "Dosing of the first subjects in the Phase 1 study is an important milestone for R
H.C. Wainwright initiated coverage of Immunic with a rating of Buy and set a new price target of $10.00
Wells Fargo reiterated coverage of Tesla with a rating of Underweight and set a new price target of $125.00 from $120.00 previously
Truist reiterated coverage of Tesla with a rating of Hold and set a new price target of $238.00 from $236.00 previously
– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea
– Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Mr. Tardio will lead in
Tesla Is Now a Texas Corporation At today's Annual Stockholders' Meeting, Tesla stockholders overwhelmingly approved the ratification of the 2018 CEO Performance Award and the redomestication of the Company to Texas. Tesla has submitted all filings to effectuate its conversion into a Texas corporation and can confirm that the Company is now incorporated in Texas. Full voting results for its 2024 Annual Meeting of Stockholders are below. AGENDA ITEM PROPOSAL BOARD VOTE RECOMMENDATIONS VOTING RESULTS Tesla Proposals 1. A Tesla proposal to elect two Class II directors, James Murdoch and Kimbal Musk, to serve for a term of three years, or until th
SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
To gain an edge, this is what you need to know today. GDP Brings Buying Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ. The drop in QQQ was triggered by speculative sentiment pulling back. As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold. Oversold markets tend to bounce. The chart shows that the volume was low on the selloff. This indicates a lack of conviction in selling. Especially hard hit in
Honda Motor Co. (NYSE:HMC) will reduce its production of gasoline vehicles in China by 19% starting this October, marking a strategic shift toward electric vehicles. The Japanese automaker will cease operations of one production line at its joint venture Dongfeng Honda, which has an annual capacity of 240,000 units, beginning in November. Additionally, in October, GAC Honda, another of its facilities with a capacity of 50,000 units annually, will be completely shut down. These changes are part of Honda's effort to accelerate the “steady shift” to EVs, reported Bloomberg. Honda’s production capacity in China, currently around 1.5 million units, will see a reduction of 19% due to
https://x.com/elonmusk/status/1816478001884004816https://x.com/elonmusk/status/1815907844434112999
4 - Tesla, Inc. (0001318605) (Issuer)
4 - Tesla, Inc. (0001318605) (Issuer)
4 - Tesla, Inc. (0001318605) (Issuer)
S-1 - APPLIED DNA SCIENCES INC (0000744452) (Filer)
144 - Tesla, Inc. (0001318605) (Subject)
PRE 14A - APPLIED DNA SCIENCES INC (0000744452) (Filer)
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Nov. 7, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, ", Relmada", , ", the Company", )), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for th
Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by YE 2024 Cash position of $54.1 million provides runway through key near-term milestones, into 2025 Management hosting conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided
CORAL GABLES, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 PM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024. Conference Call and Webcast Information:Date: Thursday, November 7, 2024 at 4:30 PM ETParticipant Dial-in (US): 1-800-717-1738Participant Dial-in (International): 1-646-307-1865Conference ID Code: 60579Webcast Access: Click Here A replay of the webcast will be available in the Investors